



DEPARTMENT OF HEALTH AND HUMAN SERVICES  
**OFFICE OF INSPECTOR GENERAL**

WASHINGTON, DC 20201



August 12, 2022

**TO:** Chiquita Brooks-LaSure  
Administrator  
Centers for Medicare & Medicaid Services

**FROM:** Suzanne Murrin  
Deputy Inspector General  
for Evaluation and Inspections

**ERIN BLISS** Digitally signed by ERIN BLISS  
Date: 2022.08.11 16:46:47  
-04'00'  
on behalf of Suzanne Murrin

**SUBJECT:** *Comparison of Average Sales Prices and Average Manufacturer Prices: Results for the First Quarter of 2022, OEI-03-22-00210*

This memorandum summarizes the results of the Office of Inspector General's (OIG's) comparison of average sales prices (ASPs) and average manufacturer prices (AMPs) for the first quarter of 2022. By law, OIG must notify the Secretary of Health and Human Services if the ASP for a particular drug exceeds the drug's AMP by 5 percent or more. If that threshold is met, the Secretary may disregard the drug's ASP when setting the reimbursement amount and substitute the lesser of either the widely available market price or 103 percent of the AMP.

In April 2013, the Centers for Medicare & Medicaid Services (CMS) began making price substitutions in accordance with the November 2012 final rule specifying the circumstances under which AMP-based price substitutions occur. Pursuant to the rule, CMS substitutes 103 percent of the AMP for the ASP-based reimbursement amount when OIG identifies a drug code that exceeds the 5-percent threshold for two consecutive quarters or three of the previous four quarters. CMS lowers reimbursement amounts only when ASP and AMP comparisons are based on the same set of drug products (i.e., based on complete AMP data). To prevent CMS from inadvertently raising the Medicare reimbursement amount, a price substitution is not implemented if the substituted amount would exceed the ASP-based payment amount for the quarter in which the price substitution would take effect. In addition, price substitutions are not implemented for drugs that the Food and Drug Administration (FDA) identifies as being in short supply.

OIG found that in the first quarter of 2022, eight drug codes met CMS's price-substitution criteria by exceeding the 5-percent threshold for two consecutive quarters or three of the previous four quarters, on the basis of complete AMP data. OIG found 10 additional drug codes that, on the basis of complete AMP data, exceeded the 5-percent threshold. However, at the time of our analysis, FDA identified these drugs as being in short supply. Another two drug codes

had ASPs that exceeded the AMPs by at least 5 percent in the first quarter of 2022, on the basis of complete AMP data, but these drug codes did not meet other CMS price-substitution criteria.

We will provide you with the results of our pricing comparison for the first quarter of 2022, as well as the results for the three previous quarters. This information will be transmitted via our secure file transfer system.